Fast Five Quiz: How Much Do You Know About Chronic Myelogenous Leukemia?

Emmanuel C. Besa, MD


August 15, 2016

Dasatinib and nilotinib have both demonstrated higher efficacy than imatinib for first-line treatment of chronic-phase CML. With the advent of tyrosine kinase inhibitors, interferon alfa is no longer considered first-line therapy for CML. Myelosuppressive therapy was formerly the mainstay of treatment to convert a patient with CML from an uncontrolled initial presentation to one with hematologic remission and normalization of the physical examination and laboratory findings. However, new agents have proven to be more effective, with fewer adverse events and longer survival.

The US Food and Drug Administration has limited the indications for use of ponatinib to the following:

  • Adult patients with T315I-positive CML in chronic, accelerated, or blast phase (or T315I-positive, Ph1-positive acute lymphoblastic leukemia)

  • Adult patients with chronic, accelerated, or blast phase CML for whom no other tyrosine kinase inhibitor therapy is indicated

For more the treatment of CML, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.